Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer

Stec, Rafał; Cierniak, Szczepan; Lubas, Arkadiusz; Brzoskowska, Urszula; Syryło, Tomasz; Zieliński, Henryk; Semeniuk-Wojtaś, Aleksandra

doi:10.1007/s12253-019-00678-1

Cited by 15 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ki67 is a DNA-bound protein activated only during the proliferation phase and is not detected during cell cycle quiescence. Studies on Ki67 in UC have reported it as a prognostic factor for recurrence and progression in upper tract UC ( 19 , 42 ) NMIBC after TURB ( 43 , 44 ). In the present study, we found a correlation between higher stages of UC and increased Ki67 expression levels.…”

Section: Discussionmentioning

confidence: 99%

Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen

et al. 2022

View full text Add to dashboard Cite

Bacillus Calmette–Guérin (BCG) is the gold standard adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). However, given the current global shortage of BCG, new treatments are needed. We evaluated tumor microenvironment markers as potential BCG alternatives for NMIBC treatment. Programmed death-ligand 1, human epidermal growth factor receptor-2 (HER2), programmed cell death-1 (PD1), CD8, and Ki67 levels were measured in treatment-naïve NMIBC and MIBC patients (pTa, pT1, and pT2 stages). Univariate and multivariate Cox proportional hazard models were used to determine the impact of these markers and other clinicopathological factors on survival, recurrence, and progression. EP263, IM142, PD1, and Ki67 levels were the highest in the T2 stage, followed by the T1 and Ta stages. HER2 and IM263 expressions were higher in the T1 and T2 stages than in the Ta stage. In NMIBC, the significant prognostic factors for recurrence-free survival were adjuvant therapy, tumor grade, and HER2 positivity, whereas those for progression-free survival included age, T-stage, and IM263. Age, T-stage, EP263, PD1, CD8, and Ki67 levels were significant factors associated with overall survival. IM263 and HER2 are potential biomarkers for progression and recurrence, respectively. Therefore, we propose HER2 as a potential target antigen for intravesical therapeutics as a BCG alternative.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Our data are consistent with most researchers’ conclusions, who also noted a correlation between the Ki-67 expression and the stage and grade of malignancy. The presence of a high Ki-67 expression might be a prognostic factor of recurrence in the near future [ 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer

Kostyev

Bondar

Chystiakov

et al. 2021

Cent european J Urol

View full text Add to dashboard Cite

Introduction Expression level of the cell proliferation marker Ki-67 correlates with the degree of differentiation of tumor cells and stage in primary patients with non-muscle-invasive bladder cancer (NMIBC), but the marker is currently not used in assessing the efficacy of adjuvant intravesical therapy and risk stratification in patients with recurrent bladder tumors. Material and methods A retroprospective study included 107 patients with high-risk NMIBC; the patients were divided into 2 groups. The first group included patients who received adjuvant therapy after transurethral resection of the bladder using the Bacillus Calmette-Guérin (BCG) vaccine (BCG therapy group; n = 54), the second group consisted of patients who received hyperthermic intravesical chemotherapy (HIVEC ® therapy group; n = 53) using the device for local hyperthermia Combat BRS HIVEC ® . Results Tumor recurrences were recorded in 21 (39%) patients receiving intravesical BCG therapy and in 9 (17%) patients after intravesical hyperthermic chemotherapy (p = 0.012). The expression level of Ki-67 in primary tumors did not differ; in recurrent tumors it was significantly different in both groups (32.05 ±13.80 vs 11.00 ± 6.86). The frequency of recurrence-free survival (RFS) in patients receiving chemohyperthermia was significantly higher than in patients after the BCG therapy (log-rank test result: p = 0.048). Conclusions Assessment of Ki-67 expression in recurrent tumors can be a criterion for the effectiveness of intravesical bladder-preserving treatment. The use of hyperthermic chemotherapy can reduce the number of radical cystectomies in a separate group of patients with NMIBC.

show abstract

“…Aberrations in Ki-67 expression are associated with worse results of histopathology and clinical outcome in patients (29). Expression of Ki-67 may provide additional information that will allow more accurate stratifi cation of the risk of NMIBC recurrence after TURBT (13).…”

Section: Discussionmentioning

confidence: 99%

“…Several reports showed that Ki-67 is an independent poor prognostic factor for NMIBC (10,11). The expression level of the Ki-67 signifi cantly correlates with recurrence rate and histopathological differentiation of the tumor (12,13).…”

Section: Introductionmentioning

confidence: 99%

The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non–muscle invasive bladder cancer

Harsanyi¹,

Žiaran²,

Bevizova³

et al. 2020

BLL

View full text Add to dashboard Cite

OBJECTIVES: The objectives of this study were to determine the prognostic value of expression levels of selected biomarkers and their statistical analysis in relation to survival and standard histopathologic examination and other clinicopathologic variables in non-muscle invasive bladder cancer (NMIBC). BACKGROUND: Worldwide, bladder cancer is a frequent malignant disease with rising incidence. Characteristic invasiveness and high recurrence rates call for more diagnostic methods to obtain more accurate information. Prognosis is affected by a signifi cant interpersonal variability of the disease. For this reason, constant search for alternative and better diagnostic methods is essential. METHODS: We analysed cancer tissue from patients with Ta and T1 bladder cancer. E-cadherin and Ki-67 expression levels were analysed using immunohistochemical staining. The expression levels quantifi ed to a percentual amount were statistically analysed in relation to survival and their frequency distribution in the study group. RESULTS: E-cadherin and Ki-67 expression levels show high association with tumor stage and grade (p<0.001), in contrast, the association with recurrence has proven insignifi cant. Patients with non-aberrant biomarker expression levels have much higher survival rates than the cases with aberrant expression. CONCLUSION: Low expression levels of Ki-67 and high expression levels of E-cadherin positively affect survival of patients, whereas aberrant expressions pose poorer prognosis (Tab. 2, Fig. 2, Ref. 33).

show abstract

Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer

Cited by 15 publications

References 28 publications

Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen

Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen

The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer

The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non–muscle invasive bladder cancer

Contact Info

Product

Resources

About